导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.18% | 1795/4773 |
| 近一周 | -1.44% | 2558/5467 |
| 近一月 | -5.29% | 2298/5421 |
| 近一季 | -7.48% | 2363/5238 |
| 近半年 | -0.47% | 1706/4931 |
| 近一年 | 5.35% | 1546/4400 |
| 近两年 | 60.08% | 1224/2954 |
| 近三年 | 39.14% | 776/2253 |
| 成立以来 | 66.96% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.49% 2323/4961 |
14.62% 1783/5312 |
- - |
- - |
| 2025 | 24.71% 1775/4813 |
0.41% 1859/3635 |
2.51% 1524/4076 |
19.93% 2076/4524 |
1.02% 1583/4813 |
| 2024 | 15.84% 877/3463 |
1.71% 859/2808 |
-2.11% 1137/3014 |
16.93% 1306/3129 |
-0.50% 1445/3463 |
| 2023 | -6.87% 878/2656 |
5.33% 798/2280 |
-3.91% 961/2385 |
-2.73% 732/2515 |
-5.41% 1346/2655 |
| 2022 | -19.78% 895/2207 |
-13.60% 795/1919 |
5.58% 869/2016 |
-12.71% 767/2113 |
0.75% 1456/2208 |
| 2021 | 1.44% 675/1822 |
-3.00% 739/1255 |
6.05% 772/1330 |
-3.23% 621/1466 |
1.92% 754/1822 |
| 2020 | 40.28% 312/1250 |
-6.23% 472/1028 |
16.63% 425/1067 |
14.38% 280/1164 |
12.14% 499/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 易方达中证800ETF联接A VS. 长安沪深300非周期A(740101) |